Niagen Bioscience
Open
$3.46
Prev. Close
$3.46
High
$3.46
Low
$3.44
Market Snapshot
$276.28M
14.8
0.10
$99.6M
117
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 117 full-time employees. The company went IPO on 2007-06-25. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 117 full-time employees. The company went IPO on 2007-06-25. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.
Recently from Cashu

Niagen Bioscience Rebrands Research Program to Advance NAD+ Knowledge and Support Emerging Scientists
Niagen Bioscience (Ticker: NAGE) enhances its commitment to scientific innovation through a comprehensive rebranding initiative. The company transitions from the ChromaDex External Research Program to…
Niagen Bioscience Announces Record Growth Plans in Anti-Aging Market
Niagen Bioscience Sets Ambitious Growth Plans Following Record Financial Success Niagen Bioscience (NASDAQ:NAGE), a frontrunner in the anti-aging product market, announces its most impressive financia…
Niagen Bioscience: Driving Growth in the Expanding Anti-Aging Market
Niagen Bioscience on the Cutting Edge of Anti-Aging Innovation Niagen Bioscience positions itself as a leading player in the burgeoning anti-aging market, recently reporting a landmark achievement wit…
Avaí Bio and Niagen Bioscience: Pioneering Innovations in the Expanding Anti-Aging Market
Avaí Bio's Strategic Advancements in Anti-Aging Therapies Avaí Bio, Inc., a trailblazer in the biotechnology sector focused on anti-aging therapies, has embarked on a significant initiative by launchi…